James R. Glynn Retires from Invitrogen Board of Directors; Former Company Leader Departs Board after Seven Years of Service

Business Wire, Feb 28, 2006

CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN) and its Board of Directors today announced that James R. Glynn will retire as a Director of the company at its annual stockholders meeting on April 21 after seven years of service. Mr. Glynn retires as Chief Executive Officer Emeritus of Invitrogen after serving the company in various leadership roles for almost a decade.

"I am extremely honored to have been able to work alongside Jim," said Gregory T. Lucier, Invitrogen's Chairman and CEO. "His leadership and integrity have been a cornerstone of Invitrogen's growth into one of the preeminent life science companies. I want to thank him for his counsel and guidance."

Mr. Glynn was elected to the Board of Directors of Invitrogen in June 1998. During his management tenure with the company from June 1998 to August 2003 he served as the Chief Financial Officer, and as the interim Chief Executive Officer. Prior to his service with Invitrogen, Jim Glynn held executive leadership roles with Matrix Pharmaceuticals, Mycogen Corporation, and Lubrizol Inc. He remains a member of the Board of Directors at Web Side Story, a Nasdaq traded company.

Upon Mr. Glynn's retirement, Invitrogen's Board of Directors will be reduced in size from ten Directors to nine, increasing the percentage of independent Directors represented.

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of $1.2 billion in 2005. For more information, visit www.invitrogen.com.

Safe Harbor Statement

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) James R. Glynn will retire as a board member of Invitrogen Corporation on April 21; and 2) Invitrogen's Board of Directors will reduce its membership from ten to nine members. Potential risks and uncertainties include, but are not limited to, the risks: a) The precise date of Mr. Glynn's retirement may vary; and b) Invitrogen may elect to increase the size of the Board of Directors in the future, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.